|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 127.88 USD | -0.95% |
|
+1.74% | -6.32% |
| 07/07 | RBC Raises Price Target on Neurocrine Biosciences to $146 From $145, Keeps Outperform Rating | MT |
| 01/07 | Neurocrine Biosciences, Inc.(NasdaqGS:NBIX) added to Russell Midcap Value Index | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| NEUROCRINE BIOSCIENCES, INC. | Other Pharmaceuticals | -0.95% | +1.74% | -6.32% | -8.05% | -0.06% | 1.28TCr |  |  | |
Technical Rankings Surperformance
- Stock Market
- Equities
- NBIX Stock
- Charts Neurocrine Biosciences, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition